Lantheus Holdings Inc (LNTH) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lantheus Holdings Inc   (NASDAQ: LNTH)

Lantheus Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Lantheus Holdings Inc in the second quarter 2026?
Lantheus Holdings Inc achieved a return on average equity (ROE) of 23.27 % in its second quarter 2026, which is below Lantheus Holdings Inc 's average return on equity, which stands at 93.7%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the In Vitro & In Vivo Diagnostic Substances industry only one company had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 530, from total ROE ranking in the first quarter 2026 at 540.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 12.43 % 4.13 % 0.16 % -5.13 % -
Y / Y Net Income Change -4.73 % 62.34 % - -78.82 % 26.87 %
Net Income (TTM) in Millions 275 279 234 168 271
Return On Equity (TTM) 23.27 % 24.33 % 20.58 % 14.78 % 23.57 %
LNTH's Total Ranking # 530 # 540 # 480 # 479 # 442
Equity (TTM) in Millions 1,312 1,212 1,090 1,119 1,167
Seq. Equity Change 8.21 % 11.24 % -2.63 % -4.08 % 0.22 %
Seq. Net Income Change -36.64 % 118.93 % 94.76 % -64.74 % 7.96 %

Back to LNTH Management Effectiveness >> LNTH's 5 Years Annual ROE >> Compare LNTH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 2
Sector # 73
Overall # 530

Return On Equity Statistics
High Average Low
2097.54 %
93.7 %
-14.26 %
(Jun 30 2018)   (Dec 31 2021)





LNTH Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 1,090 1,088 816 447 464
Y / Y Equity Change 0.16 % 33.35 % 82.47 % -3.72 % -9.68 %
Net Income in Millions 234 312 327 28 -71
Y / Y Net Income Change -25.25 % -4.35 % 1063.86 % - -
Return On Equity 21.43 % 28.72 % 40.04 % 6.28 % -15.35 %

Back to LNTH Management Effectiveness >> LNTH's 5 Years Annual ROE >> Compare LNTH ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 21.43 %, due to deterioration of net income.


More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LNTH's' Return on Equity at Yahoo Finance
LNTH's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LNTH's Competitors
Subscribers only: Roe for Lantheus Holdings Inc 's Suppliers
Subscribers only: Return On Equity for LNTH's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %

Date modified: 2026-09-26T07:21:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.